{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:13:31Z","timestamp":1790712811520,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cushing's syndrome (CS) is associated with a hypercoagulable state resulting in an increased risk on venous thromboembolism (VTE). In patients with untreated active CS VTE incidence is up to 18-fold higher compared to the general population, whereas after pituitary and adrenal surgery a postoperative VTE risk between 2.6 and 5.6% has been reported. Interestingly, after surgery the VTE risk is not only increased in the first week but also during several months postoperatively. The hypercoagulable state in CS is thought to be caused, at least in part, by an imbalance between activity of pro- and anticoagulant pathways. However, changes in activated partial thromboplastin time and plasma concentrations of pro-and anticoagulant factors are not observed in every CS patient. Only retrospective studies have shown that thromboprophylaxis lowers VTE risk in CS. Future prospective studies should asses the optimal timing, duration and type of thromboprophylaxis in CS to improve VTE-related morbidity and mortality.<\/jats:p>","DOI":"10.1007\/s11102-022-01261-9","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T03:02:48Z","timestamp":1658804568000},"page":"746-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hypercoagulability in Cushing\u2019s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols"],"prefix":"10.1007","volume":"25","author":[{"given":"Richard A.","family":"Feelders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette K.","family":"Nieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"9996","key":"1261_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927","journal-title":"Lancet"},{"issue":"4","key":"1261_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/cen.12094","volume":"78","author":"R van der Pas","year":"2013","unstructured":"van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA (2013) Hypercoagulability in Cushing\u2019s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 78(4):481\u2013488","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"1261_CR3","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1210\/jc.2009-0290","volume":"94","author":"B Van Zaane","year":"2009","unstructured":"Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E et al (2009) Hypercoagulable state in Cushing\u2019s syndrome: a systematic review. J Clin Endocrinol Metab 94(8):2743\u20132750","journal-title":"J Clin Endocrinol Metab"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fendo.2018.00805","volume":"9","author":"J Wagner","year":"2018","unstructured":"Wagner J, Langlois F, Lim DST, McCartney S, Fleseriu M (2018) Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing\u2019s syndrome: a systematic meta-analysis. Front Endocrinol (Lausanne) 9:805","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1261_CR5","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1210\/clinem\/dgaa291","volume":"105","author":"E Papakokkinou","year":"2020","unstructured":"Papakokkinou E, Olsson DS, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T et al (2020) Excess morbidity persists in patients with Cushing\u2019s disease during long-term remission: a swedish nationwide study. J Clin Endocrinol Metab 105(8):2616\u20132624","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1261_CR6","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/jc.2011-1661","volume":"96","author":"DJ Stuijver","year":"2011","unstructured":"Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR et al (2011) Incidence of venous thromboembolism in patients with Cushing\u2019s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96(11):3525\u20133532","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1261_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1210\/js.2018-00278","volume":"3","author":"B Babic","year":"2019","unstructured":"Babic B, De Roulet A, Volpe A, Nilubol N (2019) Is VTE prophylaxis necessary on discharge for patients undergoing adrenalectomy for Cushing syndrome? J Endocr Soc 3(2):304\u2013313","journal-title":"J Endocr Soc"},{"issue":"4","key":"1261_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1210\/jc.2011-2753","volume":"97","author":"R van der Pas","year":"2012","unstructured":"van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM et al (2012) The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97(4):1303\u20131310","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1261_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-10-0583","volume":"163","author":"L Manetti","year":"2010","unstructured":"Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G et al (2010) Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing\u2019s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 163(5):783\u2013791","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1261_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0030-1248723","volume":"36","author":"G Targher","year":"2010","unstructured":"Targher G, Zoppini G, Moghetti P, Day CP (2010) Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 36(1):41\u201348","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"1261_CR11","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1210\/jcem.81.6.8964868","volume":"81","author":"DA Papanicolaou","year":"1996","unstructured":"Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP (1996) Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 81(6):2303\u20132306","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1261_CR12","first-page":"10-2","volume":"30","author":"M Levi","year":"2010","unstructured":"Levi M (2010) The coagulant response in sepsis and inflammation. Hamostaseologie 30(1):10-2-14\u20136","journal-title":"Hamostaseologie"},{"issue":"2","key":"1261_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12020-015-0665-z","volume":"52","author":"M Zilio","year":"2016","unstructured":"Zilio M, Mazzai L, Sartori MT, Barbot M, Ceccato F, Daidone V et al (2016) A venous thromboembolism risk assessment model for patients with Cushing\u2019s syndrome. Endocrine 52(2):322\u2013332","journal-title":"Endocrine"},{"issue":"8","key":"1261_CR14","first-page":"3662","volume":"87","author":"M Boscaro","year":"2002","unstructured":"Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT et al (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing\u2019s syndrome. J Clin Endocrinol Metab 87(8):3662\u20133666","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1261_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","volume":"18","author":"M Barbot","year":"2015","unstructured":"Barbot M, Daidone V, Zilio M, Albiger N, Mazzai L, Sartori MT et al (2015) Perioperative thromboprophylaxis in Cushing\u2019s disease: What we did and what we are doing? Pituitary 18(4):487\u2013493","journal-title":"Pituitary"},{"issue":"4","key":"1261_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","volume":"178","author":"E Valassi","year":"2018","unstructured":"Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S et al (2018) Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 178(4):399\u2013409","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1261_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-022-02320-x","volume":"17","author":"FM van Haalen","year":"2022","unstructured":"van Haalen FM, Kaya M, Pelsma ICM, Dekkers OM, Biermasz NR, Cannegieter SC et al (2022) Current clinical practice for thromboprophylaxis management in patients with Cushing\u2019s syndrome across reference centers of the European Reference network on rare endocrine conditions (Endo-ERN). Orphanet J Rare Dis 17(1):178","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"1261_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01261-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01261-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01261-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T05:25:25Z","timestamp":1666416325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01261-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01261-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"15 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}